Synthesis and preclinical evaluation of tigilanol tiglate analogs as latency-reversing agents for the eradication of HIV

By sjmartinez • January 25, 2025

Gentry ZO, McAteer OD, Hamad JL, Moran JA, Kim JT, Marsden MD, Zack JA, Wender PA. Synthesis and preclinical evaluation of tigilanol tiglate analogs as latency-reversing agents for the eradication of HIV. Sci Adv. 2025 Jan 24;11(4):eads1911. doi: 10.1126/sciadv.ads1911. Epub 2025 Jan 24. PMID: 39854456.

Tags: Hematology/Oncology, Infectious Diseases, Publications

Patient, care partner, and provider voice in treatment decision-making for non-small cell lung cancer

Orr LD, Vanderpoel J, Vadagam P, Patel MI, Roy UB, Ledezma B, Yung M, Deering KL, Kulbokas V, Feldman J, Gray JE. Patient, care partner,[...]

Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials

Zhao S, Cheng Y, Wang Q, Li X, Liao J, Rodon J, Meng X, Luo Y, Chen Z, Wang W, Yi T, Li Y, Yin[...]

Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies

García-Saenz JA, Spera G, Pollán M, Bermejo B, Ruiz-Borrego M, Chan A, Martín M, Guerrero-Zotano Á, Calvo L, Rodríguez-Lescure Á, Marín M, Chap L, Crown[...]